Comparison of Receptor Mechanisms and Efficacy Requirements for δ-Agonist-Induced Convulsive Activity and Antinociception in Mice

  title={Comparison of Receptor Mechanisms and Efficacy Requirements for $\delta$-Agonist-Induced Convulsive Activity and Antinociception in Mice},
  author={Daniel C. Broom and Joshua F Nitsche and John E. Pintar and Kenner C. Rice and James H. Woods and John R. Traynor},
  journal={Journal of Pharmacology and Experimental Therapeutics},
  pages={723 - 729}
δ-Opioid receptor-selective agonists produce antinociception and convulsions in several species, including mice. This article examines two hypotheses in mice: 1) that antinociception and convulsive activity are mediated through the same type of δ-receptor and 2) that greater δ-agonist efficacy is required for antinociception than for convulsive activity. δ-Mediated antinociception was evaluated in the acetic acid-induced abdominal constriction assay, which involves a low-intensity noxious… 

Figures from this paper

Pharmacological Properties of δ-Opioid Receptor–Mediated Behaviors: Agonist Efficacy and Receptor Reserve
Evaluated pharmacological properties suggest that δ-receptor–mediated behaviors display a rank order of efficacy requirement, with antihyperalgesia having the highest requirement, followed by antidepressant-like effects and then convulsions.
Dopamine-independent psychostimulant activity of a delta-agonist
The present findings suggest that stimulation of either D2-like receptors or δ-opioid receptors can enhance the hyperlocomotion induced by stimulation of D1 receptors by methamphetamine and SKF81297, and the mechanism that underlies the hyperactivity caused by SNC80 may be different from that whichUnderlies the effects of morphine.
Separation of the convulsions and antidepressant-like effects produced by the delta-opioid agonist SNC80 in rats
It is suggested that delta agonist-induced antidepressant properties are independent of convulsive effects, and that it may be possible to eliminate the convulsions produced by delta agonists, further promoting their potential clinical utility.
Differential Behavioral Tolerance to the δ-Opioid Agonist SNC80 ([(+)-4-[(αR)-α-[(2S,5R)-2,5-Dimethyl-4-(2-propenyl)-1-piperazinyl]-(3-methoxyphenyl)methyl]-N,N-diethylbenzamide) in Sprague-Dawley Rats
The lack of observable tolerance to the antidepressant-like effects of SNC80 indicates that this class of compounds has potential as a novel antidepressant therapy.
Behavioral pharmacology of the mixed-action delta-selective opioid receptor agonist BBI-11008: studies on acute, inflammatory and neuropathic pain, respiration, and drug self-administration
The behavioral pharmacology of a novel, mixed-action delta-selective opioid receptor agonist, BBI-11008, suggests that the glycopeptide drug candidate possesses broad-spectrum antinociceptive and anti-allodynic activity across a range of pain-like conditions.
Non-peptidic δ opioid receptor agonists and antagonists (2000 – 2012)
This review covers literature and patents concerning non-peptidic δ opioid receptor agonists, antagonists, modulators and ligands from 2000 to 2012 and suggests it may be possible to eliminate convulsion induced by a δ receptor agonist.
Alkylation of opioid receptors by 5′‐naltrindole‐isothiocyanate injected into the nucleus accumbens of rats: Receptor selectivity and anatomical diffusion
Complete conclusions regarding the involvement of δ‐2 opioid receptors in pharmacological or physiological effects based on studies with 5′‐NTII should therefore be tempered, and for site‐directed studies it would be best to employ doses of 0.5 nmol or lower.


Convulsant activity of a non-peptidic δ-opioid receptor agonist is not required for its antidepressant-like effects in Sprague-Dawley rats
δ-Mediated convulsions do occur in rats and can be prevented without affecting the δ-mediated effects in the forced swim assay.
Convulsive effects of systemic administration of the delta opioid agonist BW373U86 in mice.
The data suggest that the convulsions as well as the tolerance induced by BW373U86 were initiated through delta opioid receptors.
Behavioral effects of the systemically active delta opioid agonist BW373U86 in rhesus monkeys.
Under the conditions evaluated in the present study, the delta receptors to which BW373U86 binds do not appear to mediate antinociceptive, respiratory depressant or reinforcing effects in monkeys.
BU48: a novel buprenorphine analog that exhibits delta-opioid-mediated convulsions but not delta-opioid-mediated antinociception in mice.
BU48 is the first described compound that produces delta-opioid-mediated convulsions without any evidence of delta-operative antinociception and will be a useful tool in investigations of the delta-OPioid receptor.
Spinal opioid delta antinociception in the mouse: mediation by a 5'-NTII-sensitive delta receptor subtype.
The present study has extended the characterization of delta-mediated antinociception effects of DPDPE and DELT after i.t. administration in mice using pretreatment with DALCE and 5'-NTII in order to selectively antagonize the delta subtypes.
Antinociceptive actions of BW373U86 in the mouse.
This study explored the antinociceptive properties of (+-)-4-[(alpha- R*)-alpha-[(2S*,5R*)-4-allyl-2,5-dimethyl-1-piperazinol]-3-hydroxy benzyl] - N,N-diethyl-benzamide dihydrochloride (BW373U86) a
A novel, potent and selective nonpeptidic delta opioid receptor agonist BW373U86.
The data suggest that BW373U86 is a potent and selective nonpeptidic delta agonist, and it elicits distinct in vivo pharmacological activities.
Delta opioid antagonist activity and binding studies of regioisomeric isothiocyanate derivatives of naltrindole: evidence for delta receptor subtypes.
The isothiocyanate group was attached to the 4'-, 5'-, 6'-, or 7'-position of naltrindole in an effort to determine the importance of the position of this electrophilic group on the selectivity for
Relative involvement of mu, kappa and delta receptor mechanisms in opiate-mediated antinociception in mice.
It was concluded that an agonist interaction with mu, but not kappa, receptors results in antinociceptive action on the radiant heat tail-flick test, and that a possible combination of mu and delta receptor interaction can result in ant inocICEptive activity in both tests.